Latest Immune Pharmaceuticals Inc. (IMNP) Headline
Post# of 34
Posted On: 03/10/2014 6:19:27 AM
Latest Immune Pharmaceuticals Inc. (IMNP) Headlines
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
IMMUNE Pharmaceuticals to Present at the 16th BIO CEO & Investor Conference
Marketwire - Thu Feb 06, 4:45PM CST
IMMUNE Pharmaceuticals Inc. (OTCQX: IMNP) (NASDAQ: IMNP) announced today that Daniel Teper, Chairman and Chief Executive Officer, will be presenting at the 16th annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 11:30AM local time at the Waldorf Astoria, Room Duke of Windsor, in New York.
LifeSci Advisors Initiates Coverage of Immune Pharmaceuticals
Marketwire - Tue Dec 10, 7:01AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP) (OTCQX: IMNP), a clinical stage biopharmaceutical company focused on developing antibody therapeutics for inflammatory diseases and cancer. Immune Pharmaceuticals' lead development program is bertilimumab, currently in Phase II clinical trials for treatment of ulcerative colitis (UC), Crohn's disease (CD) and bullous pemphigoid (BP), an orphan, autoimmune dermatological condition. Data from trials of bertilimumab in BP and CD are expected in mid-2014, and data from the UC trial is expected in the first half of 2015.
Immune Pharmaceuticals' Common Stock Approved for Trading on NASDAQ OMX First North Premier
PR Newswire Europe - Mon Nov 25, 11:01PM CST
TARRYTOWN, New York and HERZLIYA-PITUACH, Israel, Nov. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North"). The Company will transfer its common stock listing from the NASDAQ OMX Stockholm Exchange on November 29, 2013, and the first day of trading on First North will be December 2, 2013.
Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
PR Newswire Europe - Tue Nov 19, 11:02PM CST
-- GAIN ON MERGER TRANSACTION DRIVES INCREASE IN STOCKHOLDERS' EQUITY TO $7.8 MILLION
Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
PR Newswire Europe - Thu Oct 31, 11:01PM CDT
Immune Pharmaceuticals Inc. announced today that it has appointed Erik Penser Bankaktiebolag as a liquidity provider for the Company's common shares currently listed on NASDAQ OMX Stockholm Exchange under the trading symbol IMNP. The firm will continue to be the Company's liquidity provider after its planned transfer of its stock listing from NASDAQ OMX Stockholm Exchange to NASDAQ OMX First North Premier.
New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis
PR Newswire Europe - Tue Oct 15, 11:01PM CDT
-- Phase II Trial to Focus on Moderate to Severe UC Patients with Eotaxin-1 Biomarker
Immune Pharmaceuticals names two new members to board
M2 - Tue Oct 15, 5:44AM CDT
Immune Pharmaceuticals Inc (OTCQX:IMNP)(STO:IMNP) announced today that Rene Lerer, MD and Daniel Kazado have been named to its board of directors.
Immune Pharmaceuticals Announces Changes to its Board of Directors
PR Newswire Europe - Mon Oct 14, 11:02PM CDT
-- New Members Provide strong financing and operating experience
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
IMMUNE Pharmaceuticals to Present at the 16th BIO CEO & Investor Conference
Marketwire - Thu Feb 06, 4:45PM CST
IMMUNE Pharmaceuticals Inc. (OTCQX: IMNP) (NASDAQ: IMNP) announced today that Daniel Teper, Chairman and Chief Executive Officer, will be presenting at the 16th annual BIO CEO & Investor Conference on Monday, February 10, 2014 at 11:30AM local time at the Waldorf Astoria, Room Duke of Windsor, in New York.
LifeSci Advisors Initiates Coverage of Immune Pharmaceuticals
Marketwire - Tue Dec 10, 7:01AM CST
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP) (OTCQX: IMNP), a clinical stage biopharmaceutical company focused on developing antibody therapeutics for inflammatory diseases and cancer. Immune Pharmaceuticals' lead development program is bertilimumab, currently in Phase II clinical trials for treatment of ulcerative colitis (UC), Crohn's disease (CD) and bullous pemphigoid (BP), an orphan, autoimmune dermatological condition. Data from trials of bertilimumab in BP and CD are expected in mid-2014, and data from the UC trial is expected in the first half of 2015.
Immune Pharmaceuticals' Common Stock Approved for Trading on NASDAQ OMX First North Premier
PR Newswire Europe - Mon Nov 25, 11:01PM CST
TARRYTOWN, New York and HERZLIYA-PITUACH, Israel, Nov. 26, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. announced today that its common stock has been approved for trading on NASDAQ OMX First North Premier, Stockholm ("First North"). The Company will transfer its common stock listing from the NASDAQ OMX Stockholm Exchange on November 29, 2013, and the first day of trading on First North will be December 2, 2013.
Immune Pharmaceuticals Reports Third Quarter 2013 Financial Results
PR Newswire Europe - Tue Nov 19, 11:02PM CST
-- GAIN ON MERGER TRANSACTION DRIVES INCREASE IN STOCKHOLDERS' EQUITY TO $7.8 MILLION
Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange
PR Newswire Europe - Thu Oct 31, 11:01PM CDT
Immune Pharmaceuticals Inc. announced today that it has appointed Erik Penser Bankaktiebolag as a liquidity provider for the Company's common shares currently listed on NASDAQ OMX Stockholm Exchange under the trading symbol IMNP. The firm will continue to be the Company's liquidity provider after its planned transfer of its stock listing from NASDAQ OMX Stockholm Exchange to NASDAQ OMX First North Premier.
New Data Supports Clinical Rationale for Bertilimumab in Ulcerative Colitis
PR Newswire Europe - Tue Oct 15, 11:01PM CDT
-- Phase II Trial to Focus on Moderate to Severe UC Patients with Eotaxin-1 Biomarker
Immune Pharmaceuticals names two new members to board
M2 - Tue Oct 15, 5:44AM CDT
Immune Pharmaceuticals Inc (OTCQX:IMNP)(STO:IMNP) announced today that Rene Lerer, MD and Daniel Kazado have been named to its board of directors.
Immune Pharmaceuticals Announces Changes to its Board of Directors
PR Newswire Europe - Mon Oct 14, 11:02PM CDT
-- New Members Provide strong financing and operating experience
(0)
(0)